A New Model for Funding Cost-Effectiveness Research
Patients before profits
1000s of therapies and potential cures are ignored by traditional pharma due to lack of profitability. What if it were possible to reduce healthcare spending by 50-90% while helping develop such low-cost therapies?
The science is there, the patients are waiting, yet no one runs the clinical trials needed for broader adoption. With healthcare costs escalating unsustainably, we need to solve this deadly gap in funding with a new business model.
Public Good Pharma partners with health insurers to turn reduced specialty drug utilization into clinical trial funding to develop low-cost and effective therapies. We design and run self-funding Interventional Pharmacoeconomic (IVPE) trials that compare expensive specialty drugs to lower-cost alternatives, including repurposed generics, biosimilars, dose de-escalations and lifestyle interventions. This model, referred to as a “revolving research fund”, is already successfully implemented in the Netherlands.
By focusing on the most expensive categories like oncology and cell and gene therapies, we use the payer’s own cost savings during the trial to pay for high quality clinical evidence under full regulatory and ethical oversight. Payers face no financial or legal risk, yet gain the ability to reimburse the most cost-effective therapies at scale. The result is lower costs, broader access and faster, sustainable innovation in medicine, with attractive ROI for payers and real-world impact for patients
Reduce Financial Toxicity
Improve Patient Outcomes
Our incentives are aligned with patients and payers. We generate revenue by running trials that reduce pharmaceutical spend and selling higher volumes of low-cost therapies, not charging high-margins for drugs that many patients cannot access. Our long-term objective is FDA approval of cost-effective therapies that improve access and sustainability.
We work with forward-thinking payers including self-insured employers, pass-through PBMs, state health plans, and integrated health systems.
Connect with us to explore how IVPE trials can guarantee 20% cost-savings per patient during IVPE trials with a very high-likelihood of 50-90% cost-savings on the most expensive speciality drugs in your health plan while generating massive ROI from improved healthcare efficiency.
Join us to help ensure the best medicine gets funded, not the most profitable.
